Vergleichende Charakterisierung von ESBL-bildenden Escherichia coli in Diensthunden der Deutschen Bundeswehr by Böhmer, Tim Erwin
Inaugural-Dissertation zur Erlangung der Doktorwürde 
der Tierärztlichen Fakultät der Ludwig-Maximilians-
Universität München
Vergleichende Charakterisierung von ESBL-bildenden Escherichia coli in Diensthunden der 
Deutschen Bundeswehr 








Aus dem Veterinärwissenschaftlichen Department der Tierärztlichen Fakultät 
der Ludwig-Maximilians-Universität München 
 





Arbeit angefertigt unter der Leitung von  





Angefertigt am Zentralen Institut des Sanitätsdienstes der Bundeswehr 
München in Garching 
Mentor: Priv.-Doz. Dr. Julia M. Riehm 
Gedruckt mit Genehmigung der Tierärztlichen Fakultät 
der Ludwig-Maximilians-Universität München 
Dekan: Univ.-Prof. Dr. Reinhard K. Straubinger, Ph.D. 
Berichterstatter: Univ.-Prof. Dr. Reinhard K. Straubinger, Ph.D. 
Korreferent/en:  Priv.-Doz. Dr. Kristina Schauer
Tag der Promotion: 27.07.2019 
  
   
 
Für Alexia, Jakob & David 
Inhaltsverzeichnis  V 
 
   
Inhaltsverzeichnis 
I. INTRODUCTION ....................................................................................................................................... 1 
II. LITERATURE REVIEW ........................................................................................................................... 4 
1 EXTENDED-SPECTRUM BETA-LACTAMASES PRODUCING BACTERIA ................................................................4 
2 BETA-LACTAM ANTIBIOTICS ...................................................................................................................................5 
2.1 Penicillin ......................................................................................................................................................6 
2.2 Cephalosporins and cephamycins .....................................................................................................6 
2.3 Carbapenems .............................................................................................................................................7 
2.4 Beta-lactamase inhibitor (clavulanic acid, avibactam) ............................................................7 
3 MEASUREMENT OF BACTERIAL RESISTANCE .......................................................................................................8 
3.1 Agar Diffusion Method ...........................................................................................................................8 
3.2 Epsilometer Test ......................................................................................................................................8 
3.3 Broth Microdilution ................................................................................................................................9 
4 CLINICAL ASPECTS REGARDING THE USAGE OF ANTIBIOTICS ......................................................................... 10 
5 PREVALENCE OF ESBL-PRODUCING BACTERIA ............................................................................................... 10 
5.1 Birds and poultry .................................................................................................................................. 10 
5.2 Farm animals .......................................................................................................................................... 11 
5.3 Companion animals, dogs .................................................................................................................. 11 
III. PUBLICATION ........................................................................................................................................ 13 
IV. DISCUSSION ............................................................................................................................................ 40
Inhaltsverzeichnis  VI 
 
   
 
V. ZUSAMMENFASSUNG .......................................................................................................................... 46 
VI. SUMMARY ............................................................................................................................................... 48 
VII. REFERENCES .......................................................................................................................................... 50 
VIII. DANKSAGUNG ....................................................................................................................................... 59 
Index of abbreviations  VII 
 
   
Index of abbreviations 
3-APB 3-Amino-Phenyl-Borat 
AmpC ampicillin resistant gene C beta-lactamase 
C/C cefotaxime + clavulanic acid 
CAZ ceftazidime 
CDC Centre for Disease Control and Prevention 
CDS coding sequence 
CEP cefepime 
CLSI Clinical & Laboratory Standards Institute 
CMC cefepime + clavulanic acid 
COX cefoxitin 
CTB cefotaxime + 3-APB 
CTX cefotaxime 
CTX-M cefotaximase-Munich beta-lactamase 
CZB ceftazidime + 3-APB 
CZC ceftazidime + clavulanic acid 
DART Deutsche Antibiotika-Resistenzstrategie 
E. coli Escherichia coli 
ECDC European Centre for Disease Prevention and Control 
ERT ertapenem 
ESBL extended-spectrum beta-lactamases 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
GC growth control 
GC/B growth control + 3-APB 
GC/E growth control + EDTA 
I intermediate 
Index of abbreviations  VIII 
 
   
MEB meropenem + 3-APB 
MEE meropenem + EDTA 
MER meropenem 
mg/L milligram per litre 
MHK minimale Hemmkonzentration 
MIC minimal inhibitory concentration 
MLST multilocus sequence typing 
n number of isolates 
na not assigned 
NMD-1 new-Delhi metallo-beta-lactamase 1 
OXA oxacillin-hydrolyzing beta-lactamase 
R resistant 
S susceptible 
SHV sulfhydryl variable beta-lactamase 
SNP single nucleotide polymorphism 
ST sequence type 
TEM temoneira beta-lactamase 
VetCAST Veterinary Antimicrobial Susceptibility Testing 
VIM verona integron-encoded metallo-beta-lactamase 
WHO World Health Organisation 
Register of illustrations & 
List of tables   IX 
 
   
Register of illustrations 
Figure 1 Discovery and year of introduction regarding new antibiotic 
substances with the beta-lactam antibiotics in bold 
Figure 2 Publicly published warnings regarding the misuse of antimicrobial 
substances 
Figure 3 Ambler classification of beta-lactamases 
Figure 4 Setting of broth microdilution plate (Merlin) as used in the present 
study 
List of tables 
Table 1 Bush-Jacoby-Medeiros classification scheme for beta-lactamases 
Table 2 Breakpoints for minimal inhibitory concentrations (MIC) in mg/L for 
selected Enterobacteriaceae, with S (susceptible) and R (resistant) 
Table 3 Assignment of bacterial isolates according to different guidelines; S 
(susceptible), I (intermediate), R (resistant), na (not assigned) 
Table 4 Number of the isolates regarding the reaction in presence of 
ceftazidime 
I Introduction 1 
 
I. Introduction 
Bacteria are one of the earliest forms of life on earth and ever since they had to 
defense their territory against other microorganisms, fungi and further competitors [1]. 
Therefore, microbial resistance is probably as old as bacteria themselves [2].  
The microbiologist Robert Koch was one of the first who discovered the infectious character 
of microorganisms, and in 1884 he, Friedrich Loeffler and others set up the Koch's postulates 
for the characteristics and identification of infectious microorganisms [3]. In 1929, Alexander 
Fleming made the scientific discovery and found an agent of antimicrobial effect produced by 
Penicillium notatum [4-5]. Florey and Chain developed a method to extract the antibiotic 
penicillin out of Penicillium cultures that enabled the usage of this remedy during World War 
II [5]. Since then, the fast progressing development of various and inexpensive antibiotic 
substances for the use of human and animal medication shaped the Industrial Age (Fig. 1).  
 
Figure 1: Discovery and year of introduction regarding new antibiotic substances with the beta-lactam 
antibiotics in bold. 
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By then it was not to be seen yet that abundant use of antibiotic substances increases the 
selection of antimicrobial resistant bacteria almost at the same time [2]. In animal husbandry, 
antibiotics were overprescribed and (ab)used to boost profit in the meat production business 
[6]. Human medicine faces the same problems of unchecked (mis)use of antimicrobial 
substances enabling the selection of hazardous resistances (Fig. 2). Broad cognition that 
antimicrobial resistance will pose a major problem in medicine alerted different committees 
such as the World Health Organization (WHO) and the European Centre for Disease 
Prevention and Control (ECDC) [7]. As consequence, public health authorities such as the WHO 
and the American Centers for Disease Control and Prevention (CDC) publicly warned about 
the misusage of antimicrobial substances and even published posters to arise interest in the 
society to this impending problem (Fig. 2). 
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Currently, in the twenty-first century, it is a mainline challenge in medicine to handle the 
tightrope walk between therapy using antibiotics and not using these to safe resources [8]. 
Regardless of the affected discipline such as human or veterinary medicine, joint efforts need 
to be done based on the one health approach and to set a trend against antimicrobial 
resistance [9]. The present work was done with the intention to investigate the prevalence of 
ESBL-producing bacteria in military work dogs. A major task was to make a rough estimate of 
the risk for special professional groups such as dog handlers and veterinarians.  
Using a longitudinal timeline, the persistence and dynamic of these bacteria should be 
determined. Finally, and to compare the results at some epidemiological context, individual 
isolates from dogs were recovered originating from military area of operations. 
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II.  Literature review 
1 Extended-spectrum beta-lactamases producing bacteria 
Extended-spectrum beta-lactamases (ESBL) producers is a term for a subgroup of 
gram-negative bacteria, characterized by their enzymatic activity being able to destroy beta-
lactam antibiotics with extended-spectrum such as 3rd and 4th generation cephalosporins 
[10]. Extended-spectrum beta-lactamases can be categorized by their molecular structure, 
used in the classification system by Ambler in 1980 (Fig. 3). Additionally to the Ambler 
classification scheme a further major scheme is the Bush-Jacoby-Medieros classification 
scheme categorizing extended-spectrum beta-lactamases by their functionality (Table 1) [10, 
12]. 
Initially only plasmid-encoded beta-lactamases enabled to hydrolyse 3rd and 4th generation 
cephalosporins belonging to Ambler class A and D were signed as ESBL-producers [11]. A 
newer definition expands the term ESBL by Ambler class C beta-lactamases and 
carbapenemases (Fig. 3).   
 
Figure 3: Ambler classification of beta-lactamases, adapted from [11].  
 
However there is no standardized precise definition for the term ESBL in view of the fact that 
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Table 1: Bush-Jacoby-Medeiros classification scheme for beta-lactamases, adapted from [13]. 





1 Cephalosporinase No C 53 E. cloacae P99, MIR-1 
2a Penicillinase Yes A 20 S. aureus, S. epidermidis 
2b Broad-spectrum Yes A 16 TEM-1 
2be Extended-spectrum Yes A 38 TEM-3, SHV-2 
2br Inhibitor-resistant Diminished A 9 TRC-1 
2c Carbenicillinase Yes A 15 PSE-1, BRO-1 
2d Cloxacillinase Yes D or A 18 OXA-1, Streptomyces cacaoi 
2e Cephalosporinase Yes A 19 Proteus vulgaris 
2f Carbapenemase Yes A 3 E. cloacae IMI-1 
3 Metalloenzyme No B 15 Stenotrophomonas maltophilia L1 
4 Penicillinase No  7 Burkholderia cepacia 
 
 
Both schemes for the classification of beta-lactamases are useful for different aims. A precise 
definition for ESBL is not given in any of them [12].  Other systems focus on the 
epidemiological and clinical evaluation of bacterial resistance. For the mers of the present 
study we used standard guidelines published by the Clinical & Laboratory Standards Institute 
(CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for the 
classification of the isolates [15, 17-18, 20]. 
2 Beta-lactam antibiotics 
The term beta-lactam originates from the chemical structure, a beta-lactam ring. The 
group of beta-lactam antibiotics comprises in addition to the primal substance penicillin and 
its derivatives the categories of cephalosporins, carbapenems and monobactams. The 
mechanism of action of all beta-lactam antibiotics is primary bactericidal, meaning that 
bacteria are damaged by the antibiotics and their proliferative growth is inhibited [18]. The 
monobactams are playing a minor part whereas penicillins and cephalosporins are crucial 
agents for veterinary medicine of today [19]. 
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2.1 Penicillin 
There are several subgroups of penicillin. The four major subgroups are the benzylpenicillin, 
the phenoxypenicillin, the carboxypenicillin, and the acylamino-ureidopenicillin, with their 
respective derivates [5].  
The first listed benzylpenicillin is acid-labile and therefore not for oral use at monogastric 
animals. Nevertheless, there is still an indication for the parenteral or local application against 
gram-positive bacteria such as Staphylococcus species. The acid-stable penicillin also known 
as oral penicillin, with a similar prescription as the benzylpenicillin subgroup. The 
carboxypenicillin, as the third listed subgroup, belongs to the so-called extended-spectrum 
penicillins. It is prescribed against gram-negative bacteria. However, its stability against beta-
lactamases is very low [5]. The fourth subgroup, acylamino-ureidopenicillin, belongs as well 
to the extended-spectrum penicillins. It is not used in veterinary medicine [19]. It owns a high 
tissue penetration property that is a key advantage compared to all other subgroups. It is an 
antibiotic of last resort and used for special indications at hospitals [5]. 
2.2 Cephalosporins and cephamycins 
The cephems represent a group of antibiotics that contains cephalosporin derivates as well as 
cephamycins. Since 1945 the cephalosporins were further developed into now five 
generations of antibiotics [20]. Striking formulas are amongst these: cephalexin, a first 
generation cephalosporin, is effective against penicillinase-producing staphylococci and 
streptococci, as well as against most Enterobacteriaceae [21]. The 2nd generation 
cephalosporin cefoxitin was discovered in 1972, and is as well applied for the treatment of 
methicillin-susceptible staphylococci and streptococci, but works for a broader variety of 
gram-negative bacteria such as Haemophilus influenza, Enterobacter aerogenes and some 
Neisseria species [22]. Two 3rd generation cephalosporins were tested in the present work. 
Ceftazidime and cefotaxime were discovered in the 1970s. These can be applied by injection 
and are used against joint infection, meningitis, pneumonia, sepsis and infection of the urinary 
tract. The spectrum includes also anaerobes such as Bacteroides species [23-24]. 
The 4th generation cephalosporins, such as cefepime, developed in the 1990s have an even 
greater activity than 3rd generation agents. It is applied against nosocomial infections, such 
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as pneumonia caused by multiple drug-resistant microorganisms [25]. The 5th generation 
cephalosporins were not investigated in the present study. However, substances as 
ceftolozane, were developed for intra-abdominal infections or pneumonia caused by resistant 
gram-negative bacteria [26]. 
2.3 Carbapenems 
These highly effective antimicrobial agents were discovered from Streptomyces cattleya 
initally [27]. Although they exhibit a narrow spectrum against gram-positive bacteria, they can 
be applied against most Enterobacteriaceae and count to the drugs of last resort. They are 
applied against intra-abdominal infections, pneumonia and sepsis [28]. 
2.4 Beta-lactamase inhibitor (clavulanic acid, avibactam) 
As described beta-lactamase is an enzyme responsible for bacterial resistance against beta-
lactam antibiotics. It breaks open the ring structure of beta-lactam antibiotics, a strategy to 
impede the effect of beta-lactams. Pharmaceuticals were developed to inhibit the activity of 
beta-lactamases and are therefore called beta-lactamase inhibitors. 
Clavulanic acid was described in 1974 and patented in 1981 [29]. It is a natural product in the 
metabolism of the bacterium Streptomyces clavuligerus. There its chemical structure acts as 
a suicide inhibitor binding to the active site of the beta-lactamase. This process restructures 
the clavulanic acid molecule, creating an even more reactive molecule, and finally inactivates 
the beta-lactamase permanently [29]. 
Avibactam is effective against Ambler class A beta-lactamases, e.g. cefotaximase-Munich 
(CTX-M), Temoneira beta-lactamase (TEM), sulphhydryl variable beta-lactamase (SHV), 
Ambler class C, aminopenicillin-inactivating cephalosporinase (AmpC), and selected Ambler 
class D beta-lactamases, e.g. oxacillin-hydrolyzing beta-lactamase (OXA-48). In contrary, it is 
not quite effective against Ambler class B metallo-beta-lactamases, e.g. Verona integron-
encoded beta-lactamase (VIM) [30]. Only since 2013, it is used in combination with 
ceftazidime for the treatment of complicated urinary tract and severe intra-abdominal 
infections caused by antibiotic resistant pathogens [30]. 
An organism was identified as an ESBL-producer if there was a more or equal than threefold 
concentration-decrease in the minimal inhibitory concentration (MIC) for either antimicrobial 
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agent tested in combination with clavulanic acid versus the MIC of the agent when tested 
alone [14, 31]. As an example for a true ESBL-producer according to published guidelines by 
the American CLSI the listed a MIC of 8 mg/l ceftazidime and the more than three-fold 
concentration decrease in the MIC of 1 mg/l ceftazidime-clavulanic acid [15-16]. 
3 Measurement of bacterial resistance 
The measuring of antimicrobial resistance in vitro is a complex laboratory method. The 
principal is to determine the degree of growth inhibition for a specific isolate in the presence 
of an antibiotic substance. This depends upon the tested bacterial species and initially requires 
a pure culture isolate. The mere MIC is then interpreted according to the bacterial species by 
breakpoints and classified into susceptible (S), intermediate (I) and resistant (R) [32]. If the 
available guidelines, e.g. published by the EUCAST do not provide breakpoints for a certain 
bacterial species, the pharmacokinetic and pharmacodynamic modeling is required. This is 
called a non-species-related breakpoint [17]. 
3.1 Agar Diffusion Method  
The agar diffusion method is older than half a century and it is still in use today [33]. An 
antibiotic substance diffuses by gradient from a disk into the surrounding agar. The growth of 
a susceptible bacterial isolate will be inhibited at the zone of its individual MIC. The latter 
measured in millimeters is interpreted according to published guidelines into S-I-R status of 
each bacterial isolate [17]. Recent studies still use this method for phenotypic identification 
of ESBL- or AmpC-producing E. coli [34]. In the present study however, this method was not 
applied due to high sample volumes and comparability. 
3.2 Epsilometer Test 
The Epsilometer test, an in vitro diagnostic device, was developed and presented in 1988 for 
the first time. The elongated disk already includes the gradient of a specific antibiotic 
substance, which diffuses into the agar plate. Thus, an epsilon shaped inhibiting areola 
enables precise reading of the MIC directly on a scale at the disk. The reliability and 
reproducibility of the Epsilometer test is more precise compared to the original disk diffusion 
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method [35]. However, only a limited number, one or two, antibiotic substances are tested 
on one agar plate, making this method quite challenging for diversified routine testing. As 
well, the method takes more time and is also costlier than the disc diffusion method. 
3.3 Broth Microdilution 
The method of choice, as it was used in the present study, was the broth microdilution. Here, 
a standardized concentration of viable bacteria in a broth medium was transferred in each 
well of a microtiter plate. Each vial contained a specific concentration of different antibiotics 
(Fig. 4). The growth of the target isolate was therefore not restrained by any other parameter 
than its susceptibility. This method enabled the generation of MIC results at a high throughput 
rate and excellent reproducibility. Therefore, a broad variety of beta-lactam antibiotics and 
beta-lactamase inhibitors were compared on a large study panel [17, 36]. 
Figure 4: Setting of broth microdilution plate (Merlin) as used in the present study 
key: cefepime (CEP), cefepime + clavulanic acid (CMC), ceftazidime (CAZ), ceftazidime + clavulanic acid (CZC), ceftazidime + 
3-APB (CZB), cefotaxime (CTX), cefotaxime + clavulanic acid (C/C), cefotaxime + 3-APB (CTB), meropenem (MER), meropenem 
+ EDTA (MEE), meropenem + 3-APB (MEB), cefoxitin (COX), ertapenem (ERT), growth control (GC), concentrations in mg/l 
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4 Clinical aspects regarding the usage of antibiotics 
 
Beta-lactam antibiotics are highly effective drugs regarding the treatment of bacterial 
infections in small animals. They are therefore used frequently in veterinary medicine of 
companion, farm or exotic animals [12, 19, 37]. The tested antibiotic substances such as 
cefoxitin (or oxacillin), cefotaxime, ceftazidime, cefepime, and their combinations with 
clavulanic acid are frequently applied to dogs when necessary for the treatment of an 
infection. Besides, it needs to be considered that there is a well-known cross-hypersensitivity 
potential of beta-lactams for these animals [19, 37]. 
However, the increasing antimicrobial resistance especially against 3rd generation 
cephalosporins, here cefotaxime, ceftazidime, and 4th generation cephalosporins, here 
cefepime, is currently thought as a serious problem, and application in general needs to be 
well-considered [19, 38]. Even more, due to close proximity of companion animals to humans, 
the treatment of disease-causing ESBL-producers in companion animals is indisputable [39-
41]. And also, the risk of transfer of genetic elements carrying antimicrobial resistance from 
or to companion animals due to their close contact with humans, interspecies transmission, 
must not be underestimated [42]. 
5 Prevalence of ESBL-producing bacteria  
For infectious microorganisms, we often find specific reservoirs such as the horse in glanders, 
ruminants in brucellosis or the hare in tularemia [1]. As antimicrobial resistance is not a host 
specific property, bacteria expressing this feature may be identified in a variety of reservoirs, 
such as humans, livestock and companion animals, birds, but as well food, feed or even water 
[43].  
5.1 Birds and poultry  
The prevalence of ESBL-producing bacteria has been published for wild birds as well as for 
agricultural birds, such as poultry [44]. Regarding results of a screening study in the 
Netherlands, all sampled broiler farms revealed a rate of 80% positive swabs and fecal samples 
[45]. Similar results were recovered from a longitudinal study in Germany with a prevalence 
for ESBL-producing bacteria of up to 76%. This study additionally revealed that the prevalence 
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of these bacteria increases during the fattening period (35 days) of the birds [46]. 
Retrospective characterization of isolates from wild birds revealed a multidrug-resistant ESBL-
producing Salmonella Serovar Corvallis from a black kite (Milvus migrans) in Germany [47]. In 
another study, more than 500 cloacal swabs were screened for carbapenemase-producing 
Enterobacteriaceae in Australia. A total of 120 isolates originating from ten bacterial species 
were characterized and interpreted as large-scale transmission of antimicrobial resistant 
bacteria into wildlife [48]. Further studies from the countries of Mongolia and Saudi Arabia as 
well provided data regarding ESBL-producing bacteria in wild birds [49]. Wild birds do play an 
important role in the transmission of infectious microorganisms due to migration over large 
distances. Then they do function as reservoir but also as vectors [50]. 
5.2 Farm animals 
In contrast to the results regarding an increase of ESBL-producing bacteria during the 35-day 
fattening process in poultry, the prevalence of ESBL-producing bacteria decreased significantly 
in veal calves within an investigation time of eight and ten weeks [51]. The countrywide survey 
of resistant Escherichia coli revealed a prevalence of 25% for broilers, 3% for pigs, and 4% for 
cattle determined for slaughtered animals [52]. These results suggested a higher prevalence 
of resistant bacteria the more packed the animals were kept. However, the transmission 
dynamics in farm animals is highly complex, and cannot be calculated using only few 
parameters [51]. For humans one considerable transmission risk is the presence of resistant 
bacteria in the food chain [53]. A second risk for a special group of humans (e.g. veterinarians, 
farmers) is present regarding the close contact to animals. 
5.3 Companion animals, dogs 
ESBL-expressing Escherichia coli isolated from dogs were first described in 1988, following 
treatment of the dogs with beta-lactam antibiotics [54]. Since then, the presence of multidrug-
resistant bacteria has been described repeatedly for sick, but also entirely healthy companion 
animals, including dogs [55-58]. One longitudinal study occurring over eleven months 
identified a variety of ESBL-producing Enterobacteriaceae in healthy dogs with highly dynamic 
fecal shedding patterns, occurring either continuously or periodically [36, 59]. Single drug 
resistant Escherichia coli have been isolated from dogs directly after antibiotic treatment 
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already. In a direct experiment, involving animals including 24 dogs shedding of Escherichia 
coli resistant to beta-lactam antibiotics were recovered in 100% of the animals after seven-
day treatment with amoxicillin [60].  
The dog is amongst the earliest companion animals in the history of man. Therefore, it 
coevolved in a variety of functions parallel to the human societies. Ever since, dogs were used 
for guarding, working, company, and finally of course for pleasure. In all these functions this 
animal is a potential reservoir and vector of pathogens as well as antimicrobial resistant 
bacteria [61].  
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III. Publication 
The publication entitled “Phenotypic characterization and whole genome analysis of 
extended-spectrum beta-lactamase-producing bacteria isolated from dogs in Germany“ was 
published in PLOS ONE, a peer reviewed journal [36]. 
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IV. Discussion 
Today the broad field usage of antimicrobials and the associated concerns regarding 
antimicrobial resistance is discussed worldwide [7, 62]. The trend to counteract the increasing 
antimicrobial resistance has led to several actions in recent years. National committees 
publish guidelines for the prudent use of antibiotic pharmaceuticals [19]. One milestone was 
the enforcement of the national German veterinary pharmacy regulation law with rules for 
the application of antibiotics to animals [63]. According to this law, the resistance patterns of 
bacterial isolates must be determined in case of repeated or change of medication, 
rededication, or regarding therapy of flocks or regarding animals bred for specific purposes. 
De jure veterinarians must not rededicate some so called critical antibiotics, e.g. 
flourochinolones, 3rd and 4th generation cephalosporins. This enforcement was aimed at a 
reduction of the use of antibiotics, but as well as at avoiding an increase of antimicrobial 
resistance through non-suitable therapy. Since 2014, the amounts and application of 
antibiotics in animal husbandry in Germany are officially collected in a large database [36]. 
This measure is to monitor the overall tendency of consumption and to countersteer 
undesirable trends. According to DART, an affiliation of german stakeholders in the health 
sector, the amount of antimicrobial drugs in outpatient care, which is the biggest part of usage 
in human medicine remains unchanged since 2007. Participants of DART are federal 
authorities for example the Federal Ministry of Health and non governmental organisations, 
for example the German Society for Hygiene and Microbiology [64]. In veterinary medicine 
huge efforts lead to success and the quantum of delivered antimicrobial drugs has been 
reduced from 1238 metric tons in 2014 to 733 metric tons in 2017, a reducement of about 
40 % [65]. 
To measure microbial resistance, to standardize the classification of a bacterial isolate, and to 
determine the therapy of a patient, the MIC was determined and evaluated into the S-I-R 
status for many bacterial species by the EUCAST (compare 3.) [17]. The microorganisms 
studied in the present work were the ESBL-producing microorganisms selected from dog feces 
via simple selective nutrition media [36]. The in vitro analyses were carried out using 
commercially available test system for the microbouillon dilution method. To analyze the 
results, standard guidelines were applied. The CLSI provided standards for E. coli and Proteus 
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mirabilis (the latter only when clinically relevant). There was no recommendation for 
Pseudomonas aeruginosa from the CLSI, although it is a highly relevant pathogen in human 
and veterinarian diagnostics [1]. The European equivalent to CLSI is the EUCAST. This 
committee published guidelines for Enterobacteriaceae and Pseudomonas spp. tested on 
various ESBL-effective drugs [17]. Comparing the two different guidelines we found that the 
EUCAST’s criteria were stricter (Table 2). Consequently, isolate GER_EN01_1501_Eco_087 
initially classified with an intermediate status was found to be of resistant character when 
applying EUCAST guidelines (Table 3). 




Table 2: Breakpoints for minimal inhibitory concentrations (MIC) in mg/L for selected Enterobacteriaceae§, with S (susceptible) and R (resistant) 
Antimicrobial agent CLSI   EUCAST 
 criteria human isolates veterinary isolates**   
 S ≤ R >  S ≤ R > 
2nd generation Cephalosporin 
Cefoxitin (COX) 8 32  na na 
3rd generation Cephalosporin 
Ceftazidime (CAZ) 4 16 0,25 - 128 1 4 
Ceftazidime/ Clavulanic acid (CZC)*%   0,25/4 - 128/4 8 8 
Cefotaxime (CTX) 1 4 0,25 - 64 1 2 
Cefotaxime/Clavulanic acid (C/C)   0,25/4 - 64/4   
4th generation Cephalosporin 
Cefepime (CEP) 2 16  1 4 
Cefepime/ Clavulanic acid (CMC)      
Carbapenem 
Ertapenem (ERT) 0,5 2  0,5 1 
Meropenem (MER)    2 8 
§ Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis (only if clinically relevant) 
* EUCAST listed avibactam (4mg/L) instead of clavulanic acid 
** both 3rd generation cephalosporins have to be tested 
% ESBL: a > 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in combination with clavulanic acid vs the MIC of the agent when tested 
alone [31] 
na not applicable  
IV Discussion 43 
 
Furthermore, the EUCAST guidelines contained precise references for 24 individual bacteria 
species, and several bacterial groups, amongst are the Burkholderia cepacia-complex, 
Enterobacteriaceae, or the viridans group-streptococci [17]. The American CLSI structured the 
published guidelines as well according to specific microorganisms, but as well according to its 
clinical implications. For example, recommendations were published for E. coli isolated from 
the urinary tract during an infection [15-16].  
Both guidelines include warnings regarding some in vitro susceptibility of certain species, but 
may be at the same time non-effective in a patient [15-17]. The CLSI published separate 
guidelines regarding bacteria that are relevant in veterinary medicine [15-16]. In 2015, a sub-
committee for Veterinary Antimicrobial Susceptibility Testing (VetCAST) of the EUCAST was 
established [66]. However, there were no specific guidelines published yet. 
 
 
Table 3: Assignment of bacterial isolates according to different guidelines; S (susceptible), I (intermediate), R 
(resistant), na (not assigned).  
 COX CTX CAZ CEP 
In vitro MIC of isolate GER_EN01_1501_Eco_087 S 2 S 8 
Assignment according to CLSI [15] S I S I 
Assignment according to EUCAST [17] na I S R 
 
 
Various studies revealed that inoculum effects and in vitro conditions may easily affect the 
results of MIC during antibiotic susceptibility testing. In the present study we used a 
densitometer (DENSIMAT, Fa. BioMerieux Biotechnologies) to make certain, that inoculum 
effects were excluded.  As well transferring the in vitro results to the dosage of drugs for 
patients even might potentise the error regarding effective treatment [67-69]. Therefore, and 
to enhance the detection of known resistance, the interpretive criteria of MIC regarding most 
beta-lactam antibiotics, including extended-spectrum cephalosporins among 
Enterobacteriaceae were enforced in the past years [70]. The interpretation criteria published 
by the EUCAST are even stricter, and the MIC values lower, than the comparable values in 
both of the guidelines of the American CLSI, with human or veterinarian focus (Table 2) [15-
17]. For example, cefepime is a 4th generation cephalosporin, and limited for use in humans. 
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However, 89% of the dog isolates in the present study were resistant according to CLSI 
interpretation [36]. Considering the EUCAST guidelines even 93% of these isolates are 
considered as resistant to cefepime, including most of the stray dog isolates [17, 36]. 
Regarding ceftazidime, a 3rd generation cephalosporin and not recommended for veterinary 
use, the interpretation according to CLSI guidelines revealed 54% susceptible, whereas the 
interpretation according to EUCAST revealed only 14% susceptible isolates (Table 4) [15-17]. 
Further comparison of the two guidelines, it can be seen that data to certain antibiotics are 
missing (Table 2). The CLSI did not publish values for meropenem, and the EUCAST did not 
comment on cefoxitin [15, 17].  Cefoxitin is a 2nd generation cephalosporin, and is admitted 
as well as frequently used for the application in dogs and companion animals [19]. Out of the 
investigated 97 Enterobacteriaceae isolates in the present study, only 16% revealed to be 
resistant [36]. Interpreting this low percentage it may be assumed that the antimicrobial 
resistance is of other origin than previous antibiotic treatment in the namely dog. Although 
comprehensible that the two committees regarding antimicrobial resistance published 
different guidelines, this discrepancy just seems too large. Especially considering that the MIC 
guidelines greatly influence the recommendation for drug application in human or animal 
patients worldwide. 
Table 4: Number of the isolates regarding the reaction in presence of ceftazidime 
Number of isolates (n) CLSI [15] EUCAST [17] 
susceptible 53 3 
intermediate 10 39 
resistant 35 45 
total assigned isolates 98 98 
unassigned 3 3 
Currently, publications include more and more molecular results, and even data regarding 
whole genome analysis and information about coding sequences (CDSs) regarding 
antimicrobial resistance [12, 36, 39, 43, 73]. Therefore and as previously discussed the 
presence or absence of these CDSs should be taken into account or even rated equally as 
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certain MIC values. It should be considered that silent genes may be quickly activated in 
presence of an antimicrobial substance. Following this, also the non-Enterobacteriaceae 
organisms that are currently not considered in the CLSI or EUCAST guidelines for ESBL 
detection, would also be covered [12]. In the present study, Aeromonas caviae, Aeromonas 
hydrophila, Pseudomonas aeruginosa, and Pseudomonas fulva were amongst the resistant 
isolates (4%) [36]. Only very limited MIC-interpretation regarding the species Pseudomonas 
aeruginosa is currently available according to published guidelines [15-17]. The carbapenem-
resistance is a common phenomenon published for Pseudomonas species [71]. This could be 
confirmed in the present study, as the two Pseudomonas isolates revealed a MIC of 1 µg/ml, 
whereas all other isolates were completely susceptible towards ertapenem [36]. 
A predominant opinion is that ESBL-producing E. coli of animal origin are a major source of 
human infections. However, different studies revealed that about half of all hospital 
associated ESBL-producing isolates revealed the MLST sequencetype 131 [73-74]. These MLST 
ST131 ESBL-producing E. coli were not detected amongst the isolates of the present study 
[36]. We can therefore clearly support a published statement that the above-named opinion 
is oversimplified and neglected the complex transmission pathways [43]. Concluding the 
results of our study, we could bring some more insight into the broad research field of 
veterinary antimicrobial resistance. We did not find any so called human related MLST 
sequencetypes in this study, despite there can be a higher risk for special risk-groups, for 
example farmers, veterinarians or in this case dog handlers. A risk-evaluation can only be 
conducted in an one health approach, further research is mandatory. 
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V. Zusammenfassung
Die Zunahme antibiotikaresistenter  Bakterien  stellt  aktuell  ein  großes Problem 
im Bereich der klinischen Mikrobiologie dar. Komplikationen bei der Behandlung 
von Infektionskrankheiten, die auf die bakterielle Resistenz zurückzuführen sind, 
reichen von verlängerten  Behandlungszeiten  bis  hin  zu  Todesfällen.  Beta-Laktam-
Antibiotika, wie Penicilline und Cephalosporine werden in der Veterinärmedizin häufig, 
Carbapeneme nur als Reserveantibiotika angewendet. Enterobakterien können gegen diese 
Antibiotika schnell und vielfältige Resistenzen entwickeln. Bereits 1979 wurden erste Beta-
Laktamase-bildende und mit erweitertem Wirkungsspektrum „extended-spectrum“ Beta-
Laktamase-bildende (ESBL) Enterobakterien beschrieben. Seit den 1990er Jahren ist bekannt, 
dass bakterielle Resistenzen vermehrt bei antibiotikatherapierten Hunden auftreten. Heute 
weiß man, dass Menschen, eine Vielzahl an Säugetierarten und auch Vögel 
asymptomatisch mit ESBL-bildenden Enterobakterien besiedelt sein können. 
In der vorliegenden Arbeit zur Charakterisierung von ESBL-bildenden Escherichia coli 
in  Diensthunden der Bundeswehr wurden antibiotikaresistente Bakterien aus Hundekot 
isoliert. Die beprobten Tiere lebten zu diesem Zeitpunkt zeitweise mit anderen Diensthunden 
in einer Hundewache und teilweise mit weiteren Begleithunden in Privathaushalten 
zusammen. Die meisten Isolate wurden im Rahmen einer Langzeitstudie über elf 
Monate von den Diensthunden gesammelt. Letztere waren mindestens ein Jahr vor der 
ersten Probenahme bis zum Abschluss der letzten Probenahme nach elf Monaten nicht 
antibiotisch behandelt worden. Für die vorliegende Studie konnten weitere 
Bakterienisolate von streunenden Hunden aus den Einsatzgebieten der Bundeswehr 
gewonnen werden. Insgesamt wurden 101 Bakterienisolate aus Deutschland, der 
Republik Kosovo, Afghanistan, Kroatien und der Ukraine untersucht. Nach der 
klassischen mikrobiologischen Identifizierung von verdächtigen Bakterien wurde zunächst 
eine in vitro Empfindlichkeitstestung mit dem Bouillon-Mikrodilutionsverfahren 
durchgeführt. Die getesteten Substanzen stammten aus der Gruppe der Cephalosporine, 
hier Cefoxitin, Cefotaxim, Ceftazidim und Cefepim. Die drei letztgenannten 
wurden auch in Kombination mit Clavulansäure getestet. Die Testung erfolgte zudem mit 
den Carbapenem-Antibiotika Ertapenem und Meropenem. Die ermittelte minimale 
Hemmkonzentration (MHK, minimal inhibitory concentration, MIC) zeigte, dass es 
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verschiedene Resistenzmuster unter den untersuchten Isolaten gab. Keines der 101 
untersuchten Isolate war gegen eines der Carbapenem-Antibiotika resistent. 
Weiterhin wurden Vollgenomsequenzierung und -analyse der Isolate durchgeführt, um die in 
vitro Daten zu ergänzen und molekularbiologische Daten zu generieren. In Bezug auf 
Antibiotikaresistenz konnten 23 verschiedene Gene identifiziert werden, die spezifisch zu den 
identifizierten Bakterienspezies zugeordnet werden konnten und die eine Antibiotikaresistenz 
der Bakterien molekularbiologisch bewiesen. Eine molekulare Verwandtschaftsanalyse wurde 
anhand der ermittelten kanonischen single nucleotide polymorphisms (SNPs) vorgenommen. 
Die Ergebnisse zeigten für wenige Isolate eine klonale Verwandtschaft. Dies bewies eine 
direkte Tier-zu-Tier Übertragung von Isolaten aus der Langzeitstudie. Jedoch konnten diese 
Bakterienklone nur innerhalb von maximal sieben aufeinanderfolgenden Tagen isoliert 
werden, eine stabile Ausscheidung spezifischer Gene über einen längeren Zeitraum konnte 
nicht belegt werden. Schließlich wurde die Methode multi locus sequence typing (MLST) von 
den 85 antibiotikaresistenten E. coli Isolaten durchgeführt. Diese erbrachte 31 
unterschiedliche Sequenztypen (ST) von welchen die Sequenztypen ST744 (n=9), ST10 (n=8) 
und ST648 (n=6) am häufigsten vertreten waren. Der aus der Humanmedizin weltweit 
beschriebene Krankenhaus-Problemkeim mit der Beta-Lactamase CTX-M und einem MLST 
Sequenztyp ST131 wurde in der vorliegenden Studie nicht identifiziert. Die epidemiologische 
Interpretation ergab keine weitere Korrelation der Isolate aus der Langzeitstudie 
untereinander. Auch wurde keine signifikante Verwandtschaft von Isolaten mit 
unterschiedlicher geografischer Herkunft festgestellt.  
Die Ergebnisse der vorliegenden Arbeit bewiesen die hohe Prävalenz von ESBL-
produzierenden Bakterien bei (gesunden) Hunden, die keiner Antibiotikatherapie unterzogen 
worden waren. Es wurde gezeigt, dass einzelne Isolate zwischen den Tieren einer Gruppe 
übertragen wurden. Diese Bakterienklone wurden jedoch nach kurzer Zeit im Tier wieder 
eliminiert. Im Vergleich zu publizierten Daten gab es auch in dieser Studie keinen 
Anhaltspunkt, dass es Hunde-typische Isolate mit spezifischem Resistenzmuster gibt. Die 
Daten aus der Vollgenomsequenzierung konnten im Rahmen dieser Arbeit öffentlich 
publiziert werden. Für künftige Studien stehen diese daher zur Verfügung und ergänzen 
mögliche epidemiologische Fragen im spannenden Forschungsfeld über antibiotikaresistente 
Bakterien. 
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VI. Summary
Antimicrobial resistance is a growing concern in clinical microbiology today. Regarding 
the unsuccessful treatment of bacterial infections in human or animal patients, consequences 
reach from extended treatment times through complications and may end with a death of an 
individual patient due to untreatable bacterial infection. The beta-lactam antibiotics, namely 
penicillins, the cephalosporins (rarely the carbapenems) are highly used in veterinary 
medicine. Enterobacteriaceae easily develop a broad variety of antimicrobial resistance. Beta-
lactamase producing bacteria, or even more powerful „extended-spectrum“ beta-lactamase 
producing Enterobacteriaceae (ESBL) have been described since 1979. Since the 1990s 
bacterial resistance against beta-lactam antibiotics was found in dogs. Currently the 
asymptomatic colonization with extended-spectrum beta-lactamase (ESBL) producing 
Enterobacteriaceae has been described for humans, various mammal species, and birds.  
In the present study about the characterization of ESBL-producing Escherichia coli in military 
working dogs in the German Armed Forces antimicrobial resistant bacteria were recovered 
from dog feces. During the study time, the dogs lived together in a group of working dogs, but 
also stayed with companion dogs at the home of their family. Most of the isolates were 
obtained from the military working dogs within a longitudinal collection over eleven months. 
The dogs had not been treated with antibiotics during the past year until the beginning of the 
study period. More study isolates were recovered from stray dogs originating from the theatre 
of operations of the German Armed Forces. In all 101 bacterial isolates were investigated in 
the present study originating from Germany, Republic of Kosovo, Afghanistan, Croatia and 
Ukraine.  
To characterize the bacterial isolates, the in vitro antimicrobial susceptibility testing was 
carried out using the extended-spectrum cephalosporins cefoxitin, cefotaxime, ceftazidime, 
and cefepime, with the last three listed also tested in combination with clavulanic acid. As 
well, susceptibility testing was done using the carbapenem antibiotics ertapenem and 
meropenem. The determined minimal inhibitory concentration (MIC) values revealed divers 
resistance patterns against single or all investigated beta-lactam antibiotics, with none of the 
101 isolates resistant against the two tested carbapenem antibiotics.   
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Furthermore, whole genome sequence analysis was carried out to support the in vitro data 
and revealed an insight into molecular data. Regarding antimicrobial resistance 23 different 
but species-specific coding DNA sequences (CDS) were identified proving antimicrobial 
resistance on a molecular basis. A phylogenetic analysis was carried out using canonical single 
nucleotide polymorphisms (SNPs). The results revealed clonal bacterial isolates originating 
from different dogs, suggesting transmission between dogs from the same community. These 
clonal isolates however were not detected over a period longer than seven days. Finally 
performing multi locus sequence typing (MLST) out of the 85 resistant E. coli isolates identified 
31 different sequence types (ST). The most frequent ST were ST744 (n=9), ST10 (n=8), and 
ST648 (n=6), respectively. Amongst these, the world-wide human hospital-associated CTX-M 
beta-lactamase producing ST131 was not detected. Further epidemiologic interpretation did 
not support a correlation among the longitudinal isolates. There was no molecular proof of 
relationship between dog-isolates of different geographic origin.  
The data of the present thesis proof a high prevalence of ESBL-producing bacteria in healthy 
dogs, independent to prior treatment with antibiotics. It could be shown that single isolates 
were transmitted between individuals of the same community. These isolates however were 
as well eliminated after a short time. Most of the characterized bacteria revealed few 
characteristics signing them host-specific for dogs at this point. Within the present study, the 
whole genome analysis data were publicly published and are available to contribute for future 
epidemiologic questions regarding the exciting research field of antimicrobial resistant 
bacteria.  
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